Clarenta Acquires Leads To Development Expanding Early-Stage Drug Development Expertise

LONDON, Sept. 30, 2026 /CourierPR/ -- Clarenta, a European clinical development partner, has expanded its capabilities by acquiring Leads To Development (L2D), a specialist in non-clinical development and regulatory consultancy. This strategic move marks a significant step in Clarenta’s mission to become an integrated early development partner for biotech and pharmaceutical sponsors.

Based in Paris, France, L2D has been providing non-clinical development and regulatory consultancy alongside hands-on operations support for over 15 years. The company has helped biotech and pharmaceutical companies navigate the complexities of early-stage drug development, focusing on defining development pathways, gathering and assessing preclinical evidence, initiating and troubleshooting manufacturing, and creating regulatory strategies.

The acquisition of L2D by Clarenta Group, a company formerly known as Comac Medical Group, strengthens Clarenta’s ability to support biotech and pharmaceutical sponsors from preclinical drug development strategy through first-in-human clinical trials and beyond. According to Dr. Chris Smyth, CEO of Clarenta, the partnership adds specialist non-clinical, manufacturing, and regulatory expertise at the critical early stages of drug development. This expertise complements Clarenta’s existing strengths and helps sponsors connect the decisions made before the clinic with the realities of early clinical development.

Jonathan Kearsey, Managing Director and Co-Founder of Leads To Development, echoed the sentiment.

Together, Clarenta and L2D will continue to operate from their Paris headquarters as a specialist team, supporting existing and new clients. The partnership will strengthen the connection between early scientific strategy and first-in-human clinical research, ensuring that the decisions made in the preclinical phase are seamlessly integrated with the clinical development process.

Clarenta, formerly Comac Medical Group, is a European clinical development partner helping biotech and pharmaceutical companies navigate complex clinical development with clarity, foresight, and confidence. The company connects early development strategy, regulatory expertise, and clinical execution, from studies in its Phase I Unit to clinical delivery across Europe.